A/DT
PMLRARalpha/NN
transgene/NN
initiates/VBZ
murine/JJ
acute/JJ
promyelocytic/JJ
leukemia/NN
./.

The/DT
malignant/JJ
cells/NNS
of/IN
acute/JJ
promyelocytic/JJ
leukemia/NN
(/(
APL/NN
)/)
contain/VBP
a/DT
reciprocal/JJ
chromosomal/JJ
translocation/NN
that/WDT
fuses/VBZ
the/DT
promyelocytic/JJ
leukemia/NN
gene/NN
(/(
PML/NN
)/)
with/IN
the/DT
retinoic/JJ
acid/NN
receptor/NN
alpha/NN
gene/NN
(/(
RAR/NN
alpha/NN
)/)
./.
=====
To/TO
test/VB
the/DT
hypothesis/NN
that/IN
the/DT
chimera/NN
PMLRAR/NN
alpha/NN
plays/VBZ
a/DT
role/NN
in/IN
leukemogenesis/NN
,/,
we/PRP
expressed/VBD
a/DT
PMLRAR/NN
alpha/NN
cDNA/NN
in/IN
myeloid/JJ
cells/NNS
of/IN
transgenic/JJ
mice/NNS
./.
=====
PMLRAR/NN
alpha/NN
transgenic/JJ
mice/NNS
exhibited/VBD
impaired/JJ
neutrophil/NN
maturation/NN
early/RB
in/IN
life/NN
,/,
which/WDT
progressed/VBD
at/IN
a/DT
low/JJ
frequency/NN
over/IN
the/DT
course/NN
of/IN
several/JJ
months/NNS
to/TO
overt/JJ
APL/NN
./.
=====
Both/CC
the/DT
preleukemic/JJ
state/NN
and/CC
the/DT
leukemia/NN
could/MD
be/VB
transplanted/VBN
to/TO
nontransgenic/JJ
mice/NNS
,/,
and/CC
the/DT
transplanted/VBN
preleukemia/NN
could/MD
progress/VB
to/TO
APL/NN
./.
=====
The/DT
APL/NN
recapitulated/VBD
features/NNS
of/IN
the/DT
human/JJ
disease/NN
,/,
including/VBG
a/DT
response/NN
to/TO
retinoic/JJ
acid/NN
./.
=====
Retinoic/JJ
acid/NN
caused/VBD
the/DT
leukemic/JJ
cells/NNS
to/TO
differentiate/VB
in/FW
vitro/FW
and/CC
in/FW
vivo/FW
,/,
eliciting/VBG
remissions/NNS
of/IN
both/CC
the/DT
preleukemic/JJ
state/NN
and/CC
APL/NN
in/IN
mice/NNS
./.
=====
Our/PRP$
results/NNS
demonstrate/VBP
that/IN
PMLRAR/NN
alpha/NN
impairs/VBZ
neutrophil/NN
differentiation/NN
and/CC
initiates/VBZ
the/DT
development/NN
of/IN
APL/NN
./.
=====
The/DT
transgenic/JJ
mice/NNS
described/VBN
here/RB
provide/VBP
an/DT
apparently/RB
accurate/JJ
model/NN
for/IN
human/JJ
APL/NN
that/WDT
includes/VBZ
clear/JJ
evidence/NN
of/IN
tumor/NN
progression/NN
./.
=====
The/DT
model/NN
should/MD
be/VB
useful/JJ
for/IN
exploring/VBG
the/DT
molecular/JJ
pathogenesis/NN
of/IN
APL/NN
and/CC
the/DT
mechanisms/NNS
of/IN
the/DT
therapeutic/JJ
response/NN
to/TO
retinoic/JJ
acid/NN
,/,
as/RB
well/RB
as/IN
for/IN
preclinical/JJ
studies/NNS
of/IN
therapeutic/JJ
regimens/NNS
./.